site stats

J clin oncol 2013 31:845-852

WebDec 26, 2024 · Forastiere AA, et al. N Engl J Med 2003;349:2091-2098 RTOG 9111: Larynx Preservation Trial The median follow-up among surviving patients, 3.8 years Demographics: median age 59 years; 94% KPS 80; 50% N0; 68% SGL; 28% N2-3 27. P<0.001 Forastiere AA, et al. J Clin Oncol 2013;31:845-852.

An intergroup phase III comparison of standard radiation …

WebJ Clin Oncol. 2024; 36 (31): 3077–83 CrossRef Geoffrois L et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2024; 36 (31): 3077–83 CrossRef WebOct 1, 2024 · J Clin Oncol. 2013; 31: 845-852. Crossref; PubMed; Scopus (816) Google Scholar]. Nevertheless, PF-based IC + RT was superior to CRT by causing less severe late toxicity, and increasing laryngectomy-free survival (LFS) due to fewer non-cancer deaths as shown in the RTOG 91-11 trial [4. Forastiere A.A. crook and staple monmouth https://jfmagic.com

Progress on Multi-disciplinary Combined Therapy for Locally …

WebTalimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and … http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2024.22.1296 WebNov 2, 2015 · Either an increase or decrease in the immunoreactivity to GABA(A) alpha-1 subunit was observed in some patients. 31 Others have found more consistent decreases in GABAergic neurons in the peritumoral tissue identified as epileptogenic by electrocorticography as compared with normal tissue. 32 Autoradiographic studies of … crook and staple uk

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in …

Category:Contemporary Multidisciplinary Management of Sinonasal …

Tags:J clin oncol 2013 31:845-852

J clin oncol 2013 31:845-852

Epilepsy in glioma patients: mechanisms, management, and …

WebCancer Research on Prevention and Treatment 2024, Vol. 50 Issue (04): 327-333 DOI: 10.3971/j.issn.1000-8578.2024.22.1296 Progress on Multi-disciplinary Combined Therapy for Locally Advanced Hypopharyngeal Carcinoma. LUO Xi, YI Junlin: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer ... WebApr 28, 2024 · Oral cavity squamous cell carcinoma (OCSCC) is not an uncommon cancer, with approximately 30,260 new cases and 6650 deaths reported annually in the United …

J clin oncol 2013 31:845-852

Did you know?

WebPurpose To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation therapy (RT) for larynx preservation. WebJ Clin Oncol. 2013;31 (7):845-852. Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57 (1):49-60.

WebJ Clin Oncol 2013;31: 845-852. Crossref; Web of Science; ... J Clin Oncol 2013;31: 2854-2860. Crossref; Web of Science; Medline; Google Scholar. 56. Lorch JH, Posner MR, Wirth … WebJ Clin Oncol. 2013;31 (7):845-852. Epub 2012 Nov 26. Furusaka T, Matsuda A, Tanaka A, Matsuda H, Ikeda M. Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx. Acta Otolaryngol. 2013;133 (6):633-640. Epub 2013 Feb 11. Gold KA, Lee HY, Kim ES.

Web摘要 由于下咽独特的位置与功能,器官功能的保全与生存的提高同样重要,对于下咽癌的最佳保喉策略在持续探索中。 手术、放疗、化疗、分子靶向治疗以及免疫治疗等手段的不断进步,新的保喉治疗策略不断涌现。本文主要介绍下咽癌保喉治疗策略的确立、发展以及对未来 … Web J Clin Oncol. 2013;31(7):845-852. doi:10.1200/JCO.2012.43.6097 PubMed Google Scholar Crossref 25. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined …

WebMay 21, 2015 · Despite advances in the development of molecularly targeted therapies, limited improvements in overall survival have been noted among many cancer patients with solid tumors, primarily due to development of drug resistance. Accordingly, there is an unmet need for new targeted therapies and treatment approaches for cancer, especially …

http://www.zlfzyj.com/CN/abstract/abstract10225.shtml crook and thief wineWebDer Übersichtsartikel stellt verschiedene Techniken vor, wie 3‑D-organotypische Modelle, patientenabgeleitete Xenograftmodelle (PDX), organotypische multizelluläre Sphäroide und Ex-vivo-Gewebekulturen, die Tumor- wie Stromazellen gleichermaßen repräsentieren, und diskutiert Vor- und Nachteile in Bezug auf die Translation in die klinische Praxis. crook and weardale community eventsWeb1. Introduction. Alcohol-dependent liver disease (ALD) manifests as progressively worsening liver health following heavy ethanol (EtOH) ingestion, usually occurring over a period of … buffs vs uclaWebJan 1, 2003 · Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable … buff super marioWebJul 8, 2013 · Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group Journal of Clinical Oncology Journal of Clinical Oncology > List of Issues > Volume 31, Issue 23 > ORIGINAL REPORTS Head and … buff survivorWebApr 4, 2024 · J Clin Oncol. 2013;31:845-852. 5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of … buffs v uclaWebLancet Oncol. 2011;12(9):852–861. 80. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. ... J Clin Oncol. 2012;30(31):3841–3847. 97. Campos SM, Penson RT, Matulonis U, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and ... crook and weardale choral society